GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Cash from Discontinued Operating Activities

Ocugen (Ocugen) Cash from Discontinued Operating Activities : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Ocugen's Cash from Discontinued Operating Activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Ocugen received $0.00 Mil from discontinued investing activities. Ocugen's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Ocugen Cash from Discontinued Operating Activities Historical Data

The historical data trend for Ocugen's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Cash from Discontinued Operating Activities Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash from Discontinued Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ocugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ocugen Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocugen Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Ocugen's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen (Ocugen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Cash from Discontinued Operating Activities
Comparable Companies
SGMO BDTX NYMXF KPTI ABEO ALDX RLMD HOWL MIRO GMDA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
OCGN:Mexico 2H51:Germany
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Website
https://www.ocugen.com
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Executives
Junge Zhang director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu officer: CFO/CBO 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri director, officer: Chief Executive Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay officer: Chief Scientific Officer C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar director 375 PHEASANT RUN, NEWTOWN PA 18940
Kirsten Castillo director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Uday Kompella director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Marna C Whittington director 2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo officer: CAO/SVP, Finance C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian officer: Chief Financial Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti director C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355